A Multicenter, Open-Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated With Cancer

Trial Profile

A Multicenter, Open-Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated With Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Resiniferatoxin (Primary)
  • Indications Cancer pain
  • Focus Adverse reactions
  • Sponsors Sorrento Therapeutics
  • Most Recent Events

    • 23 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 06 Jul 2017 New trial record
    • 29 Jun 2017 According to a Sorrento Therapeutics media release, the U.S. FDA has authorized Investigational New Drug Application (IND) for Resiniferatoxin (RTX).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top